Dapagliflozin and Lobeglitazone both are oral hypoglycaemic agents. Both the agents are used in the treatment of diabetes mellitus type 2. Dapagliflozin is sodium glucose co-transporter 2 (SGL2) inhibitor. It was approved for treatment of T2DM in the European Union in November 2012. Lobeglitazone works by activating peroxisome proliferator activated receptor gamma (PPAR gamma). It was created in South Korea. This paper discuss various published analytical methods described in literature for estimation of Dapagliflozin and Lobeglitazone in various pharmaceutical formulations and biological sample. It includes different techniques like UV spectrophotometry, high performance liquid chromatography, high performance thin layer chromatography, liquid chromatography-mass spectrometry. This review reveals a major gap: no analytical method has yet been published for the simultaneous estimation of the combination of dapagliflozin and lobeglitazone, despite the fact that many methods exist for the medications either alone or in combination with other agents like metformin. These results emphasize the necessity of further methodological advancements to facilitate pharmacokinetic research and quality control for this particular medicinal combination.